SELLAS Life Sciences GroupSLS -1.80%25 Debt-to-Equity is 0.01 as of Mar. 2026, which is 75% below its 10-year median of 0.04. GuruFocus rates SLS with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 964 Biotechnology companies, SELLAS Life Sciences Group ranks better than 99.9% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for SELLAS Life Sciences Group's Debt-to-Equity or its related term are showing as below:
SLS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -7.34 Med: 0.04 Max: 5.31
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of SELLAS Life Sciences Group was 5.31. The lowest was -7.34. And the median was 0.04.
SLS's Debt-to-Equity is ranked better than 99.9% of 964
companies
in the Biotechnology industry
Industry Median: 0.16
vs SLS: 0.01
SELLAS Life Sciences Group (NAS:SLS) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
SELLAS Life Sciences Group Debt-to-Equity Related Terms
SELLAS Life Sciences Group Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SELLAS Life Sciences Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group (SLS) has a Debt-to-Equity of 0.01 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SELLAS Life Sciences Group and its competitors. This is 75% below median its historical median of 0.04. According to the industry distribution chart, SELLAS Life Sciences Group ranks #1 out of 964 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is SELLAS Life Sciences Group's Debt-to-Equity too high?
SELLAS Life Sciences Group's current Debt-to-Equity of 0.01 is 75% below median its 10-year median of 0.04. The Biotechnology industry median Debt-to-Equity is 0.16. SELLAS Life Sciences Group's value of 0.01 is 93.8% below this industry median. Based on the distribution chart, SELLAS Life Sciences Group ranks #1 out of 964 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's Debt-to-Equity compare to MBX and BHVN?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #1 out of 964 companies for Debt-to-Equity. This places SELLAS Life Sciences Group in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. SELLAS Life Sciences Group's value of 0.01 is 93.8% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.16, SELLAS Life Sciences Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SELLAS Life Sciences Group's current Debt-to-Equity of 0.01 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SELLAS Life Sciences Group and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current Debt-to-Equity is 0.01, which is 75% below median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01, which is 75% below median its 10-year median of 0.04 and 93.8% below the Biotechnology industry median of 0.16. SELLAS Life Sciences Group's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current Debt-to-Equity is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score
Get the complete analysis for SLS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
